Zacks Research Brokers Lower Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research note issued to investors on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.17 for the quarter, down from their previous estimate of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.63 EPS and Q1 2026 earnings at $0.45 EPS.

Other analysts have also recently issued reports about the stock. StockNews.com cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 28th. HC Wainwright restated a “buy” rating and issued a $115.00 target price on shares of Corcept Therapeutics in a report on Thursday, February 27th. Piper Sandler boosted their target price on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group increased their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $58.66 on Monday. The company has a 50-day moving average of $61.49 and a 200-day moving average of $53.95. The firm has a market cap of $6.19 billion, a price-to-earnings ratio of 46.56 and a beta of 0.61. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $75.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

Institutional Trading of Corcept Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Kestra Investment Management LLC acquired a new position in Corcept Therapeutics in the 4th quarter worth about $27,000. Canada Pension Plan Investment Board acquired a new position in Corcept Therapeutics in the fourth quarter worth approximately $40,000. National Bank of Canada FI bought a new position in Corcept Therapeutics during the fourth quarter valued at approximately $42,000. USA Financial Formulas acquired a new stake in Corcept Therapeutics in the fourth quarter valued at approximately $54,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in Corcept Therapeutics in the fourth quarter worth approximately $58,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the transaction, the insider now owns 85,318 shares of the company’s stock, valued at $4,299,174.02. The trade was a 18.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $50.54, for a total transaction of $111,188.00. The disclosure for this sale can be found here. Insiders have sold a total of 45,627 shares of company stock valued at $2,557,674 in the last three months. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.